Citi Pharma has partnered with the Chinese company Xin Weisheng to establish a state-of-the-art antibiotic manufacturing facility in Pakistan. This major initiative aims to boost access to critical medicines and significantly reduce dependence on imports.

Scheduled to begin commercial operations in 2026, the new facility will utilize aseptic, automated production lines to manufacture high-potency antibiotics, such as meropenem and piperacillin-tazobactam, in both Active Pharmaceutical Ingredients (APIs) and finished dosage forms.

Xin Weisheng will contribute advanced process technology, engineering support, and staff training to ensure seamless operations and compliance with global quality standards.

This collaboration marks a pivotal step in building Pakistan’s pharmaceutical manufacturing capacity, safeguarding medicine security, and aligning with the national goal of achieving self-reliance in essential therapies.